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Abstract Recent EU legislation for chemical sub-
stances requires a particular assessment of endocrine
disrupting properties that may cause adverse effects
in humans. Especially for pesticidal active substances,
measures concerning specific scientific criteria for
the determination of endocrine disrupting properties
should have been presented by the European Com-
mission until December 2013. But presently, no
specific science-based approach for the assessment of
these substances has been agreed upon. This paper is
discussing common scientific principles for the eval-
uation and grouping of substances with endocrine
disrupting properties that may cause adverse effects
in humans. A matrix-based approach is proposed to
be applied in various fields of scientific evaluation of
chemical substances, which is based on a scientific
evaluation of all available data that may contribute to
ensure a high level of protection of human health.
This evaluation is expected to be proportionate,
consistent and predictable to support administrative
decisions in regulatory toxicology. However, a scien-
tifically based categorisation in a decision matrix as a
backbone for specific and legally binding rules
should be performed according to the relevant EU
regulations for the aforementioned groups of sub-
stances. Considering the complexity of the matter, it
appears appropriate to base possible categorisation
on considerations in a decision matrix, which take
into account severity, reversibility, potency and con-
sistency of an adverse effect. Based on this decision
matrix it should be possible to allocate substances
falling under the WHO/IPCS definition to categorise
as endocrine disruptors (EDs) or even dispense such
substances from categorisation.
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1 Introduction
Recent EU legislation requires a particular assess-
ment of endocrine disrupting properties that may
cause adverse effects in humans for most of the
chemical substances. Especially for the approval of
active substances in plant protection products [Reg.
(EC) No 1107/2009] and biocidal products [Reg. (EU)
No 528/2012] a number of new exclusion criteria was
introduced. Measures concerning specific scientific
criteria for the determination of endocrine disrupt-
ing properties should have been presented by the
European Commission until December 2013. Such
criteria are essentially needed for approval decisions
on active substances in plant protection products
and biocidal products. But presently, no specific sci-
ence-based criteria for the assessment of substances
with endocrine disrupting properties have been
agreed upon. Within both regulations, the EU
Commission is required to present a draft of mea-
sures concerning specific scientific criteria for the
determination of endocrine disrupting properties as
soon as possible.
Recently, different sets of criteria have been dis-
cussed, addressing the challenges mentioned above
(Marx-Stoelting et al. 2011). Governmental agencies
such as the Danish EPA (Danish Ministry of the
Environment 2011), French ANSES (2012), British CRD/
German BfR (BfR and CRD 2011) and non-govern-
mental organisations like ECETOC (2009; Bars et al.
2011) or Chemtrust (2011) have made proposals avail-
able on their websites. A number of these proposals
have been summarised in a recent EU report (Kor-
tenkamp et al. 2011). Scientific issues on the
identification and characterisation of endocrine dis-
ruptors have also been discussed by expert panels at
the European level and results of these discussions
have been summarised in recent reports (EFSA Sci-
entific Committee 2013; OECD Endocrine Disrupters
Expert Advisory Group 2013). While most of the
approaches discussed have some principles in com-
mon regarding hazard identification, they also show
differences especially when it comes to proposals for
decision making concerning the regulatory exclu-
sion. Most proposals are based on the WHO/IPCS
definition for an endocrine disruptor as ‘‘…an
exogenous substance or mixture that alters func-
tion(s) of the endocrine system and consequently
causes adverse health effects in an intact organism,
or its progeny, or (sub)populations’’ (WHO/IPCS 2002).
As such they concentrate on adverse effects caused by
a substance, taking into account the mode or mech-
anism of action which has to be related to endocrine
disruption. In addition, most decision strategies
propose to use a weight of evidence approach and to
consider relevance to humans. Significant differences
remain in the way by which additional elements of
hazard characterisation like specificity, severity of
effects or doses at which effects occur could be
integrated into the regulatory decision.
Based on the different proposals, the European
Commission has drafted a roadmap on how to con-
tinue with adoption of a specific set of criteria. This
roadmap lists four options for specific criteria (see
‘‘Box 1’’, EU Commission 2014). Option 3 and 4 are
supposed to make a distinction between three dif-
ferent categories of endocrine disruptors.
Box 1: different options for sets of criteria
for identification of endocrine disruptors
as a basis for decision making as proposed
by the Commission roadmap
Option 1 No policy change (baseline). No criteria
are specified. The interim criteria based on classi-
fication and labelling set in the Biocidal Products
Regulation and the Plant Protection Products
Regulation could continue to apply.
Option 2 WHO/IPCS definition to identify endo-
crine disruptors (hazard identification).
Option 3 WHO/IPCS definition to identify endo-
crine disruptors and introduction of additional
categories based on the different strength of evi-
dence for fulfilling the WHO/IPCS definition.
Option 4 WHO/IPCS definition to identify endo-
crine disruptors and inclusion of potency as
element of hazard characterisation (hazard iden-
tification and characterisation).
Similar options have been proposed based on the
results of a BfR expert workshop in 2009. These
options have already been tested for applicability and
reproducibility in a recent impact assessment (Marx-
Stoelting et al. 2014). One result of this study was that
option 1 should not be used for the regulation of
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substances with endocrine disrupting properties
because a high level of false negative substances was
found due to a based decision on classification for
reproductive toxicity. The other options could, how-
ever, instead of being seen as alternatives, be
integrated in a stepwise procedure starting with
hazard identification based on the WHO/IPCS defi-
nition, considering strength of evidence and finally
categorising potential EDs based on elements of
hazard characterisation such as potency or severity of
effects.
Although conclusions on endocrine disruptors in a
regulatory context are required under the European
regulations on plant protection products [Reg. (EC)
No 1107/2009] and biocidal products [Reg. (EU) No
528/2012] the lack of agreed criteria makes imple-
mentation of these pieces of legislation difficult. The
present paper proposes a decision matrix for hazard
identification and characterisation of substances with
endocrine disrupting properties that may help to
overcome this difficulty.
2 Decision matrix
As part of the hazard assessment of a given substance
hazard identification, a comprehensive hazard char-
acterisation, mode of action analysis and consistency
check have to be performed in order to describe
qualitatively and if possible quantitatively the nature
of an observed effect. The criteria and weight of
evidence for this evaluation have to be set in advance
and comprise strength of evidence of all information
available and then a hazard characterisation making
use of a description of adversity, reversibility, severity
of effects, potency for a given target as well as con-
sistency of the observations. A hazard
characterisation should be part of the science-based
evaluation of endocrine disrupting effects as it is for
any other toxicological effect. This approach was
supported also by EFSA (2013). A proposal for a matrix
based integrated decision strategy is illustrated in
Fig. 1.
In brief, the proposed decision matrix could aid
regulators to group chemicals into the three cate-
gories suggested in the roadmap by taking into
account a number of criteria used in regulatory
hazard identification and characterisation. These
criteria include severity of effects, reversibility of
effects, consistency, strength of evidence and
potency. For each of these criteria a short definition is
given and subgroups are suggested to facilitate
matrix-based categorisation.
2.1 Strength of evidence
According to Hennes et al. (2014), strength of
evidence defines the degree of association
between chemical exposure and the toxicological
effect, such as the integrity of the test system,
dose–response relationship, strength of correlation
based on comparison with concurrent, or in lack
or complementation thereof historic control val-
ues and clarity of dose response. Insufficient or
limited strength of evidence would support cate-
gorisation into category 3 while sufficient strength
of evidence would support categorisation into
category 2 or 1.
2.2 Severity of effects
For severity the following working definition has
proven helpful: ‘‘A severe effect is an effect which is
either described as severe in nature or irreversible.
Typical severe effects comprise (but are not limited
to) tumours, irreversible forms of organ damage,
malformations or infertility’’ (Marx-Stoelting et al.
2014). Effects described as severe would thus support
categorisation into a higher category (cat 1 or 2) in
the decision matrix, while effects described as mild or
slight would support categorisation into a lower
category (cat 2 or 3) in the decision matrix.
2.3 Reversibility of effects
Irreversible effects (tumours, malformations, organ
loss) would generally support a category 1 decision,
while reversible effects would support categorisation
into category 2.
2.4 Consistency
Consistency refers to a situation, where several tests
(e.g. for several durations, by several routes of
administration and/or in several species) have been
made and should only be applied in such a situation.
The level of consistency increases, when an effect or a
related effect is observed in several studies and/or in
several species (if applicable) and/or confirmed by
results in several tissues and/or can be substantiated
by a conclusive mode of action. The mode of action is
actually a very important underlying biological rea-
son that defines a potential endocrine disruptor. It is
thus one of the most convincing arguments when
seen in conjunction with actual effects. The level of
consistency is higher, when an effect is observed in
two or more studies, in rats and mice or in a group of
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structurally related compounds. For many endocrine
disruptors, several target tissues exist. Here, consis-
tency is regarded higher if more than one tissue is
affected. On the other hand, if only one target tissue
in one species would be affected, than a lower cate-
gory would be more appropriate. In brief: a high
level of consistency would support categorisation
into group 1, while a lower level of consistency would
support categorisation into group 2 or 3.
2.5 Potency
Potency consideration with regard to endocrine
effects can be understood as a dose required to
induce a specific effect on targets of the endocrine
system (e.g. an unwanted, adverse effect). If the dose
required to induce this effect is low, the potency is
considered high. Hence, a higher category in the
decision matrix would be applied. Guidance values
for potency exist in the EU Regulation on Classifica-
tion, Labelling and Packaging of substances (CLP
regulation, EC 2008). They have been proposed for
hazard characterisation of substances producing
specific target organ toxicity.
3 Categories
Based on the results from hazard identification,
strength of evidence considerations and hazard
characterisation it is proposed to allocate substances
into three categories. ‘‘Box 2’’ presents the categories




















Decision matrix Cat 1 Cat 2 Cat 3




Reversibility of effect(s) irreversible reversible reversible 
Consistency high medium low
Potency for endocrine 
targets
high medium low 
Overall conclusion Cat 1 Cat 2 Cat 3
Fig. 1 Decision matrix taking
into account the roadmap
options 2–4 as part of an
integrated decision strategy.
Elements of this integrated





severity of effects, reversibility,
consistency and potency have
to be considered. MoA mode of
action
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Box 2: categories for endocrine disruptors
based on the three categories proposed in
the road map
Category 1: endocrine disruptors
Substances are placed into category 1 if their in-
trinsic properties comply with the WHO/IPCS
definition (2002) and if they are of high regulatory
concern because they meet the conditions below:
• There is sufficient information leading to the
assumption that the substances have caused
or may cause endocrine-mediated adverse
effects in humans taking into account severity,
reversibility, potency and consistency (as outlined
in Fig. 1).
Category 2: suspected endocrine disruptors
Substances are placed into category 2 if their in-
trinsic properties comply with the WHO/IPCS
definition (2002) and if they meet the following
condition:
• There is sufficient information leading to the
assumption that the substances have caused or
may cause endocrine-mediated adverse effects
in humans taking into account severity,
reversibility, potency and consistency (as out-
lined in Fig. 1).
Category 3: endocrine active substances
Substances are placed into category 3 when there is
some evidence that they affect the endocrine
system but where such evidence is insufficient to
decide whether the WHO/IPCS definition is met.
Further examination of the substances (e.g.
substance evaluation) may eventually lead to alloca-
tion into category 1 or category 2 or even dispense
such substances from grouping.
4 Conclusion
Based on the criteria described above, a decision
matrix is proposed as illustrated in Fig. 1. However, it
is not in the scope of the present paper to present
legally binding rules for risk management which are
yet to be defined under the relevant EU-Regulations.
Additionally this matrix is not applicable for the
environment. Instead of the potency based approach
proposed in Option 4 of the roadmap it uses a deci-
sion matrix as proposed in several working groups,
which will be protective of human health (adapted
from Kortenkamp et al. 2011). This ED decision matrix
is needed, taking into account elements of hazard
identification and hazard characterisation, such as
severity, strength of evidence, reversibility, consis-
tency and potency to obtain reliable, reproducible
and transparent results. It is in line with the relevant
different regulations and applies the most appropri-
ate criteria for identifying chemicals with endocrine
disrupting properties within the regulatory decision
making process. It is also in line with the advice from
both the scientific committee of the EFSA and the
Endocrine Disrupters Expert Advisory Group, who
concluded that identification should be based on ED
activity and adverse effects, coupled with a complex
decision matrix.
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